ReShape Lifesciences Profit Margin

The latest profit margin for RSLS is 15.39% as of March 2026. That compares with -48.26% in the prior-year period — up 3288.7% year over year. That is above the Healthcare sector average of 15.58%. Investors often review this figure alongside ReShape Lifesciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, RSLS's profit margin moved from -48.26% to 15.39% — a 3288.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ReShape Lifesciences's valuation or profitability profile.

Against Healthcare companies, RSLS currently prints 15.39% for profit margin, while the sector average sits near 15.58%. That is roughly 9775.5% above the sector mean. Large gaps often invite a closer look at ReShape Lifesciences's growth, margins, and balance sheet.

Profit Margin shows how effectively ReShape Lifesciences converts resources into returns. At 15.39%, RSLS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -48.26% in the prior-year period — up 3288.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RSLS's profit margin (15.39%), review year-over-year change from -48.26%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.